| Project/Area Number |
24790098
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | エンドセリン変換酵素 / 糖尿病性腎症 / 糖尿病性心筋症 / 糖尿病心筋症 / ブラジキニン / 心房性ナトリウム利尿ペプチド / アドレノメデュリン |
|---|
| Research Abstract |
We investigated the novel therapeutic mechanism of endothelin converting enzyme (ECE) inhibition toward diabetic concomitant diseases like nephropathy, cardiomyopathy, and limb ischemia by using genetically modified mice. Although ECE was known as synthetic enzyme for endothelin-1, this time, we proved the the potentiating vasodilative peptide as bradykinin, and also anti-inflammatory peptide as calcitonin gene related peptide by inhibiting their degradation. This study is the first investigation to confirm the new mechanism of ECE inhibition in diabetic complication.
|
